Cabazitaxel
Taxanes
Sold as Jevtana
- Drug class
- Taxanes
- Availability
- See label
- Routes
- Intravenous
- Markets covered
- 3
- Products on record
- 19
Overview
Cabazitaxel is an active pharmaceutical ingredient in the Taxanes group (L01CD). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 11 | May 22, 2026 |
| CA Canada | Health Canada | 6 | September 4, 2025 |
| EU European Union | EMA | 2 | January 7, 2026 |
GBUnited Kingdom· MHRA
11 products
Uses
1).
How to take
CACanada· Health Canada
6 products
Uses
Cabazitaxel for Injection in combination with prednisone or prednisolone is indicated for: • the treatment of patients with castration resistant (hormone refractory) metastatic prostate cancer previously treated with a docetaxel containing regimen.
Cabazitaxel for Injection should only be administered by a qualified healthcare professional experienced in the use of antineoplastic therapy (see 3 SERIOUS WARNINGS AND PRECAUTIONS BOX, 4 DOSAGE AND ADMINISTRATION and 12 SPECIAL HANDLING INSTRUCTIONS).
1 Pediatrics (<18 years of age) There is no indication for the use of Cabazitaxel for Injection in the pediatric population. The safety and the efficacy of cabazitaxel in children have not been established (see 10 CLINICAL PHARMACOLOGY – Special Populations and Conditions).
2 Clinical Trial Adverse Reactions, 10 CLINICAL PHARMACOLOGY, Special Populations and Conditions).
EUEuropean Union· EMA
2 products
Uses
1).
How to take
Drug interactions
Known interactions involving Cabazitaxel. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLNI187190027 · revised May 22, 2026
- [2]Health Canada (DPD) · 02553783 · revised September 4, 2025
- [3]European Medicines Agency · EMEA/H/C/005178 · revised January 7, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.